Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

This publication has 13 references indexed in Scilit:

• 320 Hemoglobin increase is independently associated with increased health-related quality of life (HRQL) in anemic interferon/ribavirin (IFN/RBV)-treated hepatitis C virus (HCV)-infected patients treated with epoetin alfa
  Hepatology, 2003
• Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis C
  Hepatology, 2003
• Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
  Gastroenterology, 2002
• Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
  New England Journal of Medicine, 2002
• Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C
  Alimentary Pharmacology & Therapeutics, 2002
• Rapid suppression of hematopoiesis by standard or pegylated interferon-α
  Gastroenterology, 2002
• Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose
  Journal of Hepatology, 2002
• Quality of life in HCV‐infection: lack of association with ALT levels
  Australian and New Zealand Journal of Public Health, 2001
• Chronic Infection with Hepatitis C Virus in Patients with Elevated or Persistently Normal Serum Alanine Aminotransferase Levels: Comparison of Hepatic Histology and Response to Interferon Therapy
  The Journal of Infectious Diseases, 2000
• Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
  Hepatology, 1997